FDG PET/CT predictive role in follicular lymphoma

Area of Science:

• Nuclear medicine imaging
• Oncology
• Hematology

Background:

• Follicular lymphoma (FL) is a common indolent non-Hodgkin lymphoma.
• Accurate prediction of treatment response and patient outcomes is crucial for managing FL.
• (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET) is increasingly used in lymphoma staging and response assessment.

Purpose of the Study:

• To evaluate the predictive value of end-treatment (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET) for progression-free survival (PFS) and patient outcomes in follicular lymphoma (FL).
• To identify potential predictive factors for PFS and patient outcome in FL patients post-treatment.

Main Methods:

• Retrospective analysis of 91 FL patients (38 indolent, 53 aggressive) undergoing FDG PET/CT scans at end-treatment.
• Scans were analyzed for disease presence (positive/negative).
• Statistical analysis included univariate and multivariate analyses of FDG PET results, tumor grading, FLIPI score, disease stage, and number of relapses concerning PFS and patient outcome.

Main Results:

• End-treatment FDG PET results significantly correlated with patient outcome (p = 0.0002).
• PET/CT demonstrated high performance: 100% sensitivity, 99% specificity, 89% positive predictive value, and 100% negative predictive value.
• Multivariate analysis identified FDG PET results (p = 0.0006892) and number of relapses (p = 0.01947) as independent predictors of PFS.

Conclusions:

• End-treatment FDG PET/CT is a highly accurate predictor of PFS and patient outcome in FL, regardless of tumor grade.
• A positive FDG PET scan at end-treatment signifies a poorer prognosis.
• Patients with multiple relapses and a positive FDG PET scan have significantly shorter PFS.